CohBar (NASDAQ: CWBR) announced that CEO Steven Engle will present a company update at the Sachs Novel Coronavirus Investment Forum from July 7-9, 2020. The focus will be on CB5064 analogs targeting COVID-19 associated acute respiratory distress syndrome (ARDS). Preclinical testing shows these analogs can activate the apelin receptor, potentially reducing lung injury severity. Additionally, these analogs may aid the three million annual ARDS patients unrelated to COVID-19. CohBar is dedicated to mitochondria-based therapeutics for chronic diseases, including type 2 diabetes and NASH.
CohBar, Inc. (NASDAQ: CWBR) was added to the US small-cap Russell 2000® Index on June 26, 2020. This reconstitution marks a significant milestone for the company, aimed at enhancing visibility among institutional investors. CohBar also raised approximately $4.4M in funding through an ATM offering coinciding with the index reconstitution. The firm specializes in developing mitochondria-based therapeutics for chronic diseases, with its lead compound, CB4211, currently in a paused Phase 1b clinical trial for NASH and obesity, alongside four preclinical programs.
CohBar, Inc. (NASDAQ: CWBR) will host its Annual Shareholder Meeting and Investor Update on June 16, 2020. The shareholder meeting begins at 1:30 p.m. ET and will be live-streamed. An investor update will follow at 5:00 p.m. ET, featuring a conference call and slide presentation. Participants can join via conference audio or Webex. CohBar focuses on developing mitochondria-based therapeutics for chronic diseases, with its lead compound CB4211 currently in a paused Phase 1b trial for nonalcoholic steatohepatitis (NASH) and obesity, due to the COVID-19 pandemic.
CohBar (NASDAQ: CWBR), a clinical-stage biotechnology company, announced that CEO Steven Engle will participate in the panel "Redefining What it Means to Get Old" at the BIO 2020 Digital Conference from June 8-12, 2020. Other panelists include leaders from Unity Biotechnology and Navitor Pharmaceuticals. The discussion will focus on breakthroughs in aging biology, particularly therapies targeting age-related diseases. Engle will also present a corporate overview of CohBar’s technology platform. CohBar specializes in mitochondria-based therapeutics for chronic diseases.
CohBar, Inc. (NASDAQ: CWBR) reported its Q1 2020 financial results, highlighting the expansion of its programs from two to five, including a new focus on COVID-19 related acute respiratory distress syndrome (ARDS). The company has initiated testing of CB5064 analogs and made progress in its antifibrotic program for idiopathic pulmonary fibrosis. Financially, CohBar reported a net loss of $4.2 million, up from $2.9 million in Q1 2019, with cash reserves of $10.2 million as of March 31, 2020. R&D and G&A expenses increased slightly compared to the previous year.
Summary not available.
Summary not available.